Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - November 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the second part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, explains how wide regional price gaps and lack of visibility in global distribution create openings for counterfeit sellers—with many now specializing in categories like oncology—who exploit platforms such as Facebook and Instagram to market fake drugs.

Counterfeiters Target Fragmented Pharma Supply Chains Through Digital Marketplaces

Articles

Payer-level reporting should do more than track performance—it must guide strategy, focus resources, and drive measurable brand impact.

Monitoring Payer-Level Performance and Planning

Podcasts

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.

Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs

In the eighth part of this roundtable discussion, supply chain experts emphasize that effective manufacturing strategies depend on product type, market location, and regulatory complexity, requiring a careful balance between outsourcing, internal production, regional distribution, and patient-centric priorities.

Peer Exchange: Pharma Leaders Stress Tailored, Balanced Approach to Long-Term Manufacturing Strategy (Episode 8)

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to support safe use, adherence, and management of related chronic health needs.

Goodpath Partners With GiftHealth to Expand Access to GLP-1 Therapies Through LillyDirect

As over half of Americans now receive prescriptions through Medicare or Medicaid, pharma companies must shift from a commercial-first approach to a statutory-first model, making GTN governance a C-suite priority for long-term brand survival.

Gross-to-Net Bubble Reshapes Drug Pricing Strategy

This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price increase for Mounjaro in the UK, and long-term research confirming the safety of aluminum in childhood vaccines.

Pharma Pulse: US API Stockpile Plan, Mounjaro Price Hike in UK, and New Data on Vaccine Safety

In the second part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, outlines how the impact of a steep pharmaceutical import tariff varies across raw materials, components, and finished products, along with why such a policy could incentivize companies to shift production to the US.

How a 250% Tariff Might Ripple Through Pharma Supply Chains and Spur Domestic Production

Two Labs’ Michael Rowe assesses the industry’s level of preparation, including challenges stakeholders have encountered along the way. 

DSCSA Compliance Has Arrived. Now What?

The directive calls for building a six-month Strategic Active Pharmaceutical Ingredients Reserve, updating the essential medicines list, and prioritizing US-made APIs.

Featured Content

Pharmaceutical Commerce - November 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead